MW 375.8 Da, Purity >95%. Potent and selective PDE10A inhibitor (IC50 values are 17 and 284 nM for PDE10A and PDE3A respectively). Shows smooth muscle relaxant, antispasmodic and vasodilatory effects in vivo. Orally active.
1,8-cineole 2-exo-monooxygenase, ACLS, Albendazole monooxygenase, Albendazole sulfoxidase, CP33, CP34, CP3A4_HUMAN, CYP3, CYP3A, CYP3A3, CYP3A4, CYPIIIA3, CYPIIIA4, Cytochrome P450 3A3, Cytochrome P450 3A4, Cytochrome P450 HLp, Cytochrome P450 NF-25, Cytochrome P450 family 3 subfamily A polypeptide 4, Cytochrome P450 subfamily IIIA polypeptide 4, Cytochrome P450-PCN1, DNA binding protein, ERR a, ERR-alpha, ERR1 protein, ERR1_HUMAN, ESRL 1, ESRR A, Estrogen receptor related 1, Estrogen receptor-like 1, Estrogen-related receptor alpha, Estrra, GCPS, GLI Kruppel family member GLI 3, GLI Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome), GLI family zinc finger 3, GLI3 C-terminally truncated form, GLI3 form of 190 kDa, GLI3 form of 83 kDa, GLI3 full length protein, GLI3-190, GLI3-83, GLI3FL, GLI3_HUMAN, Glioma associated oncogene family zinc finger 3, Glucocorticoid inducible P450, HLP, MGC126680, NF 25, NR3B1, Nifedipine oxidase, Nuclear receptor subfamily 3 group B member 1, Oncogene GLI3, P450 III steroid inducible, P450 PCN1, P450, family III, P450C3, PAP A, PAPB, PPD IV, Quinine 3-monooxygenase, Steroid hormone receptor ERR1, Taurochenodeoxycholate 6-alpha-hydroxylase, Transcriptional activator GLI3, Transcriptional repressor GLI3R, Zinc finger protein GLI 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, estrogen receptor related receptor alpha, hERR1
MW 375.8 Da, Purity >95%. Potent and selective PDE10A inhibitor (IC50 values are 17 and 284 nM for PDE10A and PDE3A respectively). Shows smooth muscle relaxant, antispasmodic and vasodilatory effects in vivo. Orally active.
Soluble in ethanol.
Soluble in DMSO.
Potent and selective PDE10A inhibitor (IC50 values are 17 and 284 nM for PDE10A and PDE3A respectively). Shows smooth muscle relaxant, antispasmodic and vasodilatory effects in vivo. Orally active.
Gli3 Cytochrome P450 3A4 (CYP3A4) and Estrogen-Related Receptor Alpha (ERRα) are distinct yet significant biological targets with specific mechanical functions. Gli3 operates as a transcription factor belonging to the GLI family with a mass around 158 kDa and it is predominantly expressed in the brain. CYP3A4 is a critical enzyme weighing approximately 57 kDa found abundantly in the liver and intestine responsible for the metabolism of many xenobiotics and drugs. ERRα with a mass about 49 kDa functions as a nuclear receptor and is highly expressed in tissues with high metabolic demand such as the heart and muscle.
Gli3 plays a fundamental role in the modulation of the Hedgehog signaling pathway involving itself in the transcription of target genes that are important for development. It often functions in complex with other GLI proteins modulating gene expression. CYP3A4 contributes as the main enzyme for drug metabolism influencing the pharmacokinetics of countless substances and transforming them into inactive or active forms. ERRα regulates gene expression involved in mitochondrial biogenesis and oxidative metabolism often interacting as a monomer rather than forming a complex.
Gli3 is significant in the Hedgehog pathway closely interacting with proteins like Patched and Smoothened to regulate cellular growth and differentiation. CYP3A4 is integral to the metabolic pathway of drug metabolism and detoxification collaborating with proteins such as NADPH-cytochrome P450 reductase. While ERRα is pivotal in the estrogen signaling pathway influencing cellular energy balance and collaborating with coactivators like peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α).
Gli3 mutations and misregulation associate strongly with developmental disorders such as Greig cephalopolysyndactyly syndrome often along with other GLI proteins. CYP3A4's involvement in drug metabolism connects it to disorders such as drug-induced liver injury where it often works interactively with other cytochrome P450 enzymes like CYP2C19. ERRα's influence on energy metabolism links it to metabolic disorders such as type 2 diabetes interacting with proteins involved in metabolic pathways.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab144859, Papaverine hydrochloride, PDE10A inhibitor
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com